This session offered a candid look at the implementation challenges that surfaced under the updated Physician Fee Schedule Final Rule, practical guidance on compiling documentation that holds up, and step-by-step approaches to building standardized processes and quality controls that make future submissions cleaner.
Gross-to-net can shape commercialization strategy as much as it shapes financial reporting, but many life sciences teams still treat it as a back-office exercise. This guide breaks down where Gross-to-Net models go wrong, how to build more adaptable forecasting, and what lifecycle-based support can look like in practice.
Stay ahead of the curve on the Medicaid Drug Rebate Program’s Final Rule, which takes effect on November 19, 2024, using our comprehensive white paper packed with valuable insights on what provisions could impact different manufacturers and key operational and financial factors to consider.
This piece explores key risks of pricing specialty therapies — from gross-to-net forecasting and inflation penalties to value-based agreements, IRA impacts, and state transparency laws — and shows why strategic government pricing can become a competitive advantage.
If you’d like to continue the conversation or learn more about how Riparian supports pricing for biopharma manufacturers, we’d be glad to connect.
One global partner.
Smarter, faster solutions
for life sciences
© 2001–2026 Envision Pharma Group. All rights reserved.
